|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
SG175409A1
(en)
|
2009-05-02 |
2011-12-29 |
Genzyme Corp |
Gene therapy for neurodegenerative disorders
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
ES2605305T3
(es)
|
2010-04-23 |
2017-03-13 |
University Of Massachusetts |
Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
|
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
CN105755044A
(zh)
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
CN105377039A
(zh)
*
|
2013-05-15 |
2016-03-02 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
CN105247044B
(zh)
|
2013-05-31 |
2021-05-07 |
加利福尼亚大学董事会 |
腺相关病毒变体及其使用方法
|
|
WO2015038958A1
(en)
|
2013-09-13 |
2015-03-19 |
California Institute Of Technology |
Selective recovery
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
WO2015142941A1
(en)
|
2014-03-17 |
2015-09-24 |
Avalanche Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
EA034355B1
(ru)
|
2014-05-02 |
2020-01-30 |
Джензим Корпорейшн |
Векторы на основе aav для генной терапии в сетчатке и cns
|
|
BR112016025819B1
(pt)
*
|
2014-05-14 |
2022-08-16 |
Universitat Autònoma De Barcelona |
Vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
JP2018506304A
(ja)
|
2015-02-10 |
2018-03-08 |
ジェンザイム・コーポレーション |
バリアントＲＮＡｉ
|
|
WO2016130591A2
(en)
|
2015-02-10 |
2016-08-18 |
Genzyme Corporation |
Enhanced delivery of viral particles to the striatum and cortex
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11021519B2
(en)
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
CA2979229A1
(en)
*
|
2015-03-11 |
2016-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
EP3277819B1
(en)
|
2015-03-24 |
2021-03-03 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
KR20250048140A
(ko)
|
2015-04-06 |
2025-04-07 |
서브도메인, 엘엘씨 |
드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
AU2016332821B2
(en)
|
2015-09-28 |
2022-02-17 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
WO2017100671A1
(en)
|
2015-12-11 |
2017-06-15 |
California Institute Of Technology |
TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
|
|
AU2016372035B2
(en)
*
|
2015-12-15 |
2023-03-30 |
Genzyme Corporation |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
WO2017136536A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US20190071681A1
(en)
*
|
2016-02-26 |
2019-03-07 |
University Of Florida Research Foundation, Incorporated |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
AU2017268382B2
(en)
|
2016-05-18 |
2023-09-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
KR102526506B1
(ko)
*
|
2016-07-08 |
2023-05-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
|
|
US11458211B2
(en)
|
2016-07-12 |
2022-10-04 |
The University Of Manchester |
Gene therapy
|
|
KR20230039779A
(ko)
|
2016-07-29 |
2023-03-21 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
|
|
CN109890966A
(zh)
*
|
2016-08-16 |
2019-06-14 |
北卡罗来纳-查佩尔山大学 |
用于靶向基因转移的方法和组合物
|
|
WO2018035503A1
(en)
*
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
|
CA3073137A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Jeffrey S. Bartlett |
Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
|
|
WO2018035457A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Calimmune, Inc. |
Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190057110A
(ko)
|
2016-09-28 |
2019-05-27 |
코바, 인크. |
치료적 mots-c 관련 펩타이드
|
|
US11078238B2
(en)
|
2016-09-29 |
2021-08-03 |
University Of Florida Research Foundation, Incorporated |
AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
CA3046347A1
(en)
|
2016-12-07 |
2018-06-14 |
University Of Florida Research Foundation, Incorporated |
Il-1ra cdnas
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
WO2018156892A1
(en)
|
2017-02-23 |
2018-08-30 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
MX2019012113A
(es)
|
2017-04-14 |
2020-09-10 |
Univ Nat Taiwan |
Terapia génica para la deficiencia de la aadc.
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
CN111108198A
(zh)
*
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質（ａａｐ）依存性を改変する方法および組成物
|
|
CN110997693A
(zh)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
τ聚集抑制剂
|
|
KR102766238B1
(ko)
|
2017-06-30 |
2025-02-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
|
|
TWI832036B
(zh)
|
2017-08-03 |
2024-02-11 |
美商航海家醫療公司 |
用於aav之遞送之組合物及方法
|
|
BR112020003571A2
(pt)
|
2017-08-28 |
2020-08-25 |
The Regents Of The University Of California |
variantes capsidiais de vírus adenoassociado e métodos de uso das mesmas
|
|
WO2019060649A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
|
AR113134A1
(es)
|
2017-09-22 |
2020-01-29 |
Genzyme Corp |
Arni variante
|
|
AU2018338188B2
(en)
|
2017-09-22 |
2025-02-20 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
CN111601884A
(zh)
*
|
2017-10-16 |
2020-08-28 |
维格内罗有限责任公司 |
Aav载体
|
|
EP3697448A1
(en)
*
|
2017-10-20 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant aav9-derived vector
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
US11730763B2
(en)
|
2017-11-14 |
2023-08-22 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
SI3710590T1
(sl)
*
|
2017-11-15 |
2024-10-30 |
The Regents Of The University Of Michigan |
Virusni vektorji, ki obsegajo kodirne regije RDH12 in postopke zdravljenja retinalnih distrofij
|
|
BR112020009579A2
(pt)
*
|
2017-11-15 |
2020-10-13 |
Friedrich Miescher Institute For Biomedical Research |
promotor específico de célula do epitélio de pigmento da retina de primata
|
|
JP7522656B2
(ja)
|
2017-11-21 |
2024-07-25 |
クリスパー セラピューティクス アーゲー |
常染色体優性網膜色素変性の処置のための材料および方法
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
US20210017509A1
(en)
*
|
2018-03-23 |
2021-01-21 |
The Trustees Of Columbia University In The City Of New York |
Gene Editing for Autosomal Dominant Diseases
|
|
CN112272672A
(zh)
|
2018-04-03 |
2021-01-26 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
WO2019195444A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
JP7425738B2
(ja)
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
US12378576B2
(en)
|
2018-04-27 |
2025-08-05 |
Spacecraft Seven, Llc |
Gene therapy for CNS degeneration
|
|
MA52631A
(fr)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics Inc |
Compositions et méthodes pour le traitement de la maladie de parkinson
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
WO2019221992A1
(en)
*
|
2018-05-15 |
2019-11-21 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
CA3102095A1
(en)
*
|
2018-06-01 |
2019-12-05 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for treatment of dominant retinitis pigmentosa
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
PH12021550254A1
(en)
|
2018-08-03 |
2023-02-06 |
Genzyme Corp |
Variant rnai against alpha-synuclein
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
AU2019346447A1
(en)
|
2018-09-26 |
2021-04-29 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
US20210348196A1
(en)
*
|
2018-10-10 |
2021-11-11 |
Wisconsin Alumni Research Foundation |
Kir 7.1 gene therapy vectors and methods of using the same
|
|
EP3863662A1
(en)
*
|
2018-10-12 |
2021-08-18 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
CN113227126A
(zh)
*
|
2018-11-26 |
2021-08-06 |
巴塞罗那自治大学 |
成纤维细胞生长因子21(fgf21)基因治疗
|
|
CA3121247A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
BR112021013140A2
(pt)
*
|
2019-01-04 |
2021-11-30 |
Ultragenyx Pharmaceutical Inc |
Construções de terapia gênica para tratar doença de wilson
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
AU2020212026B2
(en)
*
|
2019-01-23 |
2025-10-09 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel AAV virus enhanced by rational design
|
|
AU2020216135A1
(en)
|
2019-01-28 |
2021-08-05 |
Cohbar, Inc. |
Therapeutic peptides
|
|
ES2968922T3
(es)
|
2019-02-04 |
2024-05-14 |
Freeline Therapeutics Ltd |
Polinucleótidos
|
|
JP7597380B2
(ja)
*
|
2019-03-04 |
2024-12-10 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
|
|
JP7549360B2
(ja)
*
|
2019-03-04 |
2024-09-11 |
デューク ユニバーシティ |
網膜症の診断および処置のための組成物および方法
|
|
EP3935076A1
(en)
*
|
2019-03-08 |
2022-01-12 |
Université Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
CA3133453A1
(en)
|
2019-03-21 |
2020-09-24 |
Daniel Mccoy |
Recombinant adeno-associated virus vectors
|
|
MX2021012184A
(es)
*
|
2019-04-10 |
2022-01-24 |
Prevail Therapeutics Inc |
Terapias genicas para trastornos lisosomales.
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
CA3139852A1
(en)
*
|
2019-05-13 |
2020-11-19 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
AU2020278960A1
(en)
*
|
2019-05-17 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
|
EP3980447A4
(en)
*
|
2019-06-10 |
2023-07-26 |
Homology Medicines, Inc. |
ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR ARSA GENE TRANSFER AND METHODS OF USE THEREOF
|
|
EP3989982A4
(en)
|
2019-06-27 |
2023-06-28 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
HUE069369T2
(hu)
*
|
2019-07-15 |
2025-02-28 |
Meiragtx Uk Ii Ltd |
Módosított AAV tokfehérjék ízületi gyulladásos betegségek kezelésére
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
WO2021041324A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
WO2021046169A1
(en)
*
|
2019-09-03 |
2021-03-11 |
University Of Cincinnati |
Methods and compositions for the treatment of als
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4041755A4
(en)
*
|
2019-10-10 |
2023-10-25 |
Solid Biosciences Inc. |
MODIFIED AAV CAPSIDS AND USES THEREOF
|
|
AU2020367532A1
(en)
*
|
2019-10-17 |
2022-05-12 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
|
|
IL292372A
(en)
*
|
2019-10-23 |
2022-06-01 |
Univ Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
MX2022009252A
(es)
*
|
2020-01-29 |
2022-11-09 |
Genzyme Corp |
Proteinas de la capside de virus adeno-asociados modificadas para la terapia genica ocular y metodos de uso de las mismas.
|
|
WO2021159069A2
(en)
*
|
2020-02-07 |
2021-08-12 |
The Trustees Of Columbia University In The City Of New York |
Reprogramming the metabolome to delay onset or treat neurodegeneration
|
|
US20230013145A1
(en)
*
|
2020-02-18 |
2023-01-19 |
The University Of North Carolina At Chapel Hill |
Aav capsid-promoter interactions and cell selective gene expression
|
|
US12258566B2
(en)
*
|
2020-02-28 |
2025-03-25 |
University Of Massachusetts |
Oligonucleotides for PRNP modulation
|
|
MX2022011177A
(es)
*
|
2020-03-11 |
2022-12-13 |
Massachusetts Eye & Ear Infirmary |
Terapia genica para la degeneracion de la retina asociada a nmnat1.
|
|
US20230138766A1
(en)
*
|
2020-03-31 |
2023-05-04 |
University Of Massachusetts |
Aav capsids variants and uses thereof
|
|
US20230151390A1
(en)
*
|
2020-04-14 |
2023-05-18 |
Genethon |
Vectors for the treatment of acid ceramidase deficiency
|
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US20230203102A1
(en)
|
2020-05-13 |
2023-06-29 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529503A
(ja)
*
|
2020-06-13 |
2023-07-10 |
オクロジェネクス インコーポレイテッド |
網膜症のためのａａｖ媒介性遺伝子導入
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
MX2023000815A
(es)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos neurologicos relacionados con la deficiencia de glucosilceramidasa beta.
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
JP2023536618A
(ja)
|
2020-08-05 |
2023-08-28 |
スペースクラフト セブン リミテッド ライアビリティ カンパニー |
Ｃｓｒｐ３（システイン及びグリシンリッチタンパク質３）遺伝子治療
|
|
JP2023538519A
(ja)
|
2020-08-07 |
2023-09-08 |
スペースクラフト セブン リミテッド ライアビリティ カンパニー |
Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
|
|
KR20230068444A
(ko)
|
2020-08-19 |
2023-05-17 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
레트 증후군의 치료를 위한 아데노 관련 바이러스 벡터
|
|
CA3191543A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Lei Cao |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
US20240229072A9
(en)
*
|
2021-02-22 |
2024-07-11 |
The Regents Of The University Of Colorado, A Body Corporate |
Viral vector-based gene therapy for ocular conditions
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
CA3216809A1
(en)
*
|
2021-04-26 |
2022-11-03 |
Brendan BEAHM |
Compositions and methods for treating ngyl1 deficiency
|
|
WO2022235566A1
(en)
*
|
2021-05-03 |
2022-11-10 |
North Carolina State University |
Compositions and methods related to the treatment of ocular diseases in equines
|
|
EP4399314A4
(en)
*
|
2021-09-06 |
2025-09-10 |
Huidagene Therapeutics Singapore Pte Ltd |
TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CN118525098A
(zh)
|
2021-11-29 |
2024-08-20 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
WO2023183623A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
WO2023202637A1
(en)
*
|
2022-04-19 |
2023-10-26 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Recombinant aav vectors for treating neurodegenerative disorders
|
|
US20250171778A1
(en)
*
|
2022-04-25 |
2025-05-29 |
Myrtelle Inc. |
Treatments of Disorders of Myelin
|
|
AU2023260469A1
(en)
|
2022-04-25 |
2024-11-14 |
Cell Cure Neurosciences, Ltd. |
Methods and compositions for treating vision loss
|
|
KR20250007619A
(ko)
|
2022-05-06 |
2025-01-14 |
노파르티스 아게 |
신규 재조합 aav vp2 융합 폴리펩티드
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
CN119907694A
(zh)
|
2022-07-08 |
2025-04-29 |
圣拉斐尔医院有限责任公司 |
转基因盒
|
|
EP4555097A2
(en)
*
|
2022-07-12 |
2025-05-21 |
The Research Institute at Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|